Healthcare AI Trends 2026

This report is scoped deliberately narrower than a general adoption survey. Halkwinds' companion report, "Healthcare AI Adoption Trends 2026," already documents how health systems are deploying AI across clinical, administrative, and operational functions; readers looking for deployment-rate breakdowns by function should start there. This report instead asks a forward-looking question: given that adoption has already happened at scale, what regulatory, administrative, and data-architecture forces will determine which organizations can scale that adoption profitably and safely through 2028?

The healthcare AI market sits at an unusual inflection point. Unlike the first wave of digital health investment (2012-2019), which was driven primarily by point-solution vendors chasing venture funding, the current wave is driven by health systems and payers making infrastructure-level decisions — EHR platform selection, AI governance committee formation, and multi-year regulatory strategy — that will not be easily reversed. Halkwinds Research estimates that decisions being made in 2026 about EHR-AI integration architecture and regulatory posture will shape health system AI capability through at least 2030.

Three structural forces define this moment, and each receives dedicated treatment later in this report: a regulatory landscape that is maturing but still incomplete, an administrative automation layer that has proven ROI faster than clinical AI and is now absorbing a disproportionate share of investment, and an EHR fragmentation problem that acts as a hard ceiling on how far any individual AI deployment can scale without a data interoperability strategy underneath it. Health systems that treat these as sequential problems — regulation, then administration, then interoperability — are, in Halkwinds' analysis, underestimating how tightly coupled the three have become.

“The question for health system leadership is no longer whether AI works — it's whether the organization can scale it faster than its own regulatory, administrative, and data-architecture debt accumulates.”

This report draws on Halkwinds Research primary data collected between Q3 2025 and Q1 2026 from 312 health systems, spanning academic medical centers, community hospitals, integrated delivery networks (IDNs), ambulatory specialty groups, and payer-affiliated provider organizations. Respondents were healthcare technology decision-makers — CIOs, CMIOs, VPs of Digital Health, and Chief AI/Data Officers — at organizations ranging from single-facility community hospitals to national IDNs operating 40-plus facilities. The sample skews toward organizations with at least one AI initiative in production, which should be read as a lens on scaling dynamics among AI-active organizations rather than a market-wide adoption census.

Geographic composition of the sample is approximately 46% North America, 29% Europe, 18% Asia-Pacific, and 7% other regions (including the Middle East), reflecting both the concentration of large IDNs in the United States and the regulatory salience of the FDA SaMD pathway and the EU AI Act to this report's central focus. Point estimates in this report carry an estimated margin of error of ±5.5 percentage points at a 95% confidence level for the full sample; subgroup estimates (e.g., by hospital bed size or region) carry wider margins in the ±7-9 point range given smaller cell sizes.

Halkwinds applies a strict attribution discipline across this report, and every statistic in it falls into exactly one of three categories. Statistics presented without attribution are Halkwinds Research estimates derived from this survey wave and are consistent with — and where applicable build directly on — the key findings published alongside this report. Statistics attributed to a named third party (Gartner, IDC, McKinsey, Deloitte, Forrester, or a government/regulatory body such as the FDA or European Commission) are drawn from that organization's publicly available research or regulatory text and are cited as such; Halkwinds does not restate third-party figures as its own data. Passages framed as "Halkwinds analysis" or "in Halkwinds' assessment" are qualitative interpretation by Halkwinds researchers, not survey-derived statistics, and should be read accordingly.

No survey respondent was a Halkwinds client at the time of participation, and no compensation was provided for participation, consistent with the independence protocol used across all Halkwinds Research publications, including the flagship Enterprise AI Adoption Trends 2026 report.

• Sample: 312 health systems, Q3 2025-Q1 2026
• Geography: ~46% North America, 29% Europe, 18% APAC, 7% other
• Margin of error: ±5.5 points overall (95% CI); ±7-9 points for subgroups
• Attribution tiers: Halkwinds Research estimate / named third-party citation / Halkwinds analysis (qualitative)
• Independence protocol: no client respondents, no compensated participation

Halkwinds Research estimates the healthcare AI market at $45.2B in 2025, growing at a 32.9% CAGR to reach approximately $187.4B by 2030 — a trajectory that would outpace the broader enterprise AI market by roughly five percentage points annually across the period. This growth is occurring against a backdrop that industry analysts including Gartner and IDC have separately characterized as a broader enterprise AI investment supercycle, with healthcare consistently identified as one of the highest-growth verticals given the combination of acute labor shortages, regulatory-grade documentation burden, and diagnostic workflows that are well suited to AI augmentation.

Structural drivers behind this growth rate are distinguishable from cyclical hype. First, administrative AI has demonstrated measurable, near-term ROI (73% of health systems report at least one function in production) in a way that de-risks further investment for skeptical finance committees. Second, EHR incumbents — principally Epic and Oracle Health — have shifted from treating AI as a third-party add-on to embedding native AI capability directly into their platforms, which lowers the integration cost of subsequent AI deployments for organizations on those platforms. Third, reimbursement and workforce pressure — a persistent clinical and administrative staffing shortage across nearly every health system segment — has made automation a budget-defensible line item rather than a discretionary innovation spend.

Growth is not uniform across market segments. Clinical AI (decision support, diagnostic imaging, RAG-based documentation) is growing faster in relative terms — RAG deployment for clinical documentation has gone from a niche pilot category to 34% penetration in roughly two years — but administrative AI still represents the larger absolute share of near-term spend because it faces a lower regulatory and clinical-liability bar. Halkwinds Research expects this gap to narrow over the report's 2026-2030 horizon as regulatory pathways for clinical AI mature and as EHR-native AI reduces the marginal cost of each additional clinical deployment.

Healthcare AI's current trajectory is best understood as the product of four overlapping waves rather than a single continuous adoption curve. The first wave (roughly 2011-2016) was dominated by rule-based clinical decision support — sepsis alerting, drug interaction checking, early-warning scores — embedded directly into early EHR platforms. These systems established clinician trust (and, in some cases, alert-fatigue skepticism) that still shapes adoption attitudes toward AI-driven clinical tools today.

The second wave (2017-2021) brought the first wave of FDA-cleared machine learning diagnostic tools, concentrated heavily in radiology, ophthalmology, and pathology imaging AI. This period established the FDA's initial Software as a Medical Device (SaMD) clearance patterns and gave health systems their first operational experience with regulated, continuously learning clinical software — experience that proved foundational once generative AI entered clinical workflows several years later.

The third wave (2020-2023) was defined by pandemic-driven acceleration of telehealth, remote patient monitoring, and administrative automation, as health systems under acute capacity strain adopted automation for scheduling, triage, and revenue cycle functions that had previously moved slowly through procurement. This wave normalized AI as an operational tool rather than a research curiosity inside the C-suite, setting the stage for board-level AI investment discussions.

The current, fourth wave (2023-present) is defined by generative AI and, specifically, by RAG architectures entering clinical documentation and administrative workflows at scale. Ambient clinical documentation (AI scribes) emerged as the first mainstream generative AI clinical use case, and its success — alongside a maturing FDA SaMD guidance framework and the EU's 2024 AI Act formally classifying many clinical AI systems as high-risk — has pushed health system leadership to treat AI governance as core infrastructure rather than a pilot-stage afterthought. 2026 is, in Halkwinds' assessment, the year in which agentic AI workflows begin entering the administrative layer (prior authorization, denial management) at a pace comparable to how RAG entered documentation in 2024-2025.

• 2011-2016: rule-based clinical decision support embedded in early EHR platforms
• 2017-2021: first FDA-cleared ML diagnostic imaging tools (radiology, pathology, ophthalmology)
• 2020-2023: pandemic-driven telehealth, remote monitoring, and administrative automation acceleration
• 2023-2025: generative AI and RAG enter clinical documentation; EU AI Act classifies clinical AI as high-risk
• 2026 and beyond: agentic AI workflows begin entering prior authorization and revenue cycle at scale

The dominant global trend is the shift from pilot-stage experimentation to platform-level investment. Health systems that once ran dozens of disconnected AI pilots are consolidating around a smaller number of strategic AI platforms — often anchored to their EHR vendor's native AI capability or to a small set of governance-approved third-party platforms — because the operational and compliance overhead of managing many disparate point solutions has become unsustainable at enterprise scale.

RAG has become the default architecture pattern for grounding generative AI in clinical and administrative data, precisely because it does not require retraining a model on protected health information and can be scoped, audited, and access-controlled at the retrieval layer. Halkwinds Research views the 34% deployment figure for RAG in clinical documentation as an early indicator of a broader pattern: RAG is becoming the preferred architecture wherever a health system needs to ground generative AI output in EHR data, payer policy documents, or clinical guidelines without the governance risk of fine-tuning on sensitive data.

A second global trend is the migration of AI investment from purely clinical use cases toward the administrative-clinical boundary — prior authorization, utilization review, and denial management — where payers have already deployed AI aggressively and providers are responding in kind. Halkwinds Research characterizes this as a bottom-up forcing function: providers are not adopting administrative AI purely for efficiency but because payer-side AI adoption has changed the competitive dynamics of revenue cycle management, compressing response times and raising the cost of manual processes.

Finally, vendor consolidation is accelerating globally as the market matures. The speculative, undifferentiated point-solution vendors that proliferated between 2018 and 2022 are being acquired by health IT incumbents, running out of runway, or narrowing into defensible clinical niches with genuine regulatory clearance and outcomes evidence. Health systems evaluating vendors today have access to more mature outcomes data and more realistic implementation timelines than early adopters faced, but they also face a narrower and more consolidated vendor landscape than existed even two years ago.

Regional regulatory posture is now a primary determinant of healthcare AI deployment velocity, and the differences between major markets are widening rather than converging.

Healthcare AI deployment patterns differ meaningfully across provider sub-verticals, and treating "healthcare AI" as a single market obscures important variation in regulatory exposure, EHR architecture, and administrative economics.

The dominant clinical AI architecture pattern to emerge from this research cycle is retrieval-augmented generation (RAG) grounded in a health system's EHR and clinical knowledge base rather than fine-tuned models trained on protected health information. RAG deployments for clinical documentation typically pair a vector database indexing de-identified or access-controlled clinical content with an LLM inference layer and a retrieval and citation mechanism that lets clinicians trace generated text back to source documentation — an auditability requirement that both clinical risk management and, increasingly, regulators expect. Halkwinds' CareAxis platform is built around this pattern, combining a FHIR-native data layer with retrieval-scoped generation and built-in model monitoring for exactly this reason.

EHR integration architecture remains the most consequential technical decision health systems make. Epic's App Orchard marketplace and native predictive model infrastructure, and Oracle Health's comparable capabilities, have become de facto deployment standards for organizations on those platforms; AI tools that surface natively inside clinician workflows see materially higher utilization than standalone tools requiring separate logins or manual data transfer. For organizations managing the 3.2-systems-per-network fragmentation problem, a FHIR R4 integration façade — normalizing multiple EHRs into a canonical clinical data model without requiring EHR replacement — has emerged as the more pragmatic architecture than deep, EHR-specific point integrations.

Beyond documentation, computer vision remains the most mature clinical AI modality by regulatory track record, with diagnostic imaging (radiology triage, pathology augmentation, retinal screening) benefiting from nearly a decade of FDA clearance precedent and moving toward standardized, increasingly commoditized deployment patterns. NLP applications beyond documentation — clinical coding support, prior authorization narrative generation, and structured data extraction from unstructured notes — represent the fastest-growing non-documentation NLP category, closely tied to the administrative AI ROI case described elsewhere in this report.

Model governance infrastructure — clinical AI oversight committees, continuous model performance monitoring, and clinician feedback loops — is increasingly treated as a core architectural layer rather than a policy afterthought. Halkwinds' analysis is that health systems deploying generative or agentic clinical AI without a monitoring and audit-trail layer built in from the start are accumulating governance debt that becomes materially more expensive to retrofit once a tool is embedded in live clinical workflows.

Total cost of ownership for enterprise clinical AI deployment extends well beyond platform licensing, and Halkwinds Research analysis of engagement data indicates that integration engineering and regulatory compliance work together frequently rival or exceed licensing cost as a share of first-year TCO. The major cost components health systems should budget for are: platform or model licensing; EHR integration engineering (materially higher for organizations managing multiple EHR systems, consistent with the fragmentation finding elsewhere in this report); regulatory and compliance work, including HIPAA risk assessment and, where applicable, SaMD regulatory filing support; clinician change management and training; and ongoing model performance monitoring, which is a recurring rather than one-time cost.

Budget benchmarking is complicated by the wide variance in EHR environment complexity across health systems — an organization with a single EHR platform faces a materially different integration cost profile than one managing 3-4 systems following M&A activity. Halkwinds' cost guidance for healthcare application development and EHR-specific development provides detailed benchmark ranges by project scope; health systems evaluating clinical AI investment should treat integration and compliance cost estimation as a distinct planning exercise from platform selection, not a downstream implementation detail.

A distinct and frequently underestimated cost category is HIPAA compliance engineering specific to AI workloads — encryption, audit logging, business associate agreement (BAA) coverage for AI vendors, and de-identification pipeline validation — which differs meaningfully from general HIPAA compliance cost for non-AI systems given the additional model-training and inference-logging surface area AI introduces. Health systems that treat AI-specific HIPAA compliance as an extension of existing compliance budget, rather than a distinct line item, consistently underbudget this category in Halkwinds' engagement experience.

• Major TCO components: platform licensing, EHR integration engineering, regulatory/compliance, change management, ongoing model monitoring
• Integration cost scales with EHR fragmentation — multi-EHR networks face materially higher first-year integration spend
• AI-specific HIPAA compliance (BAA coverage, audit logging, de-identification validation) is a distinct and frequently underbudgeted cost category
• Ongoing model monitoring is a recurring operating cost, not a one-time implementation line item

Where AI-assisted diagnosis has reached production maturity, health systems in this research report a 23% reduction in diagnostic errors and a 17% reduction in preventable readmissions — outcomes that move healthcare AI's value proposition from theoretical to measurable at the population-health level. These figures are drawn from health systems with mature, production-stage deployments rather than early pilots, and Halkwinds Research treats them as representative of achievable outcomes once an organization has moved past initial deployment friction, not as a guaranteed result of AI adoption alone.

Administrative AI's benefit case is more immediately financial than clinical: 73% of health systems now report administrative AI in production in at least one function, most commonly revenue cycle management and prior authorization, precisely because these functions offer clear, auditable ROI without direct clinical liability exposure. Halkwinds' analysis is that administrative AI's faster, clearer ROI case has made it the practical funding mechanism that allows many health systems to build the AI governance infrastructure and organizational muscle later applied to higher-stakes clinical AI deployments.

RAG-based clinical documentation, now at 34% deployment, delivers benefits that are less immediately quantifiable in the outcome metrics tracked elsewhere in this report but are consistently cited by health system leadership as a top driver of clinician satisfaction and retention — a meaningful consideration given the acute clinical workforce shortage most health systems are managing concurrently with their AI investment. Halkwinds Research treats clinician time recovered from documentation burden as a benefit category that is real but harder to benchmark consistently across organizations than the diagnostic-accuracy and readmission figures above, and cautions against treating vendor-reported time-savings claims in this category as independently verified without organization-specific measurement.

EHR fragmentation is the single largest cited barrier to scaling healthcare AI, and this report's finding of an average 3.2 EHR systems per large health network — largely a legacy of M&A activity that consolidated facilities faster than it consolidated their underlying data infrastructure — outranks budget constraints, clinician trust, and technical talent availability as the primary obstacle health system leadership cites. Every additional EHR system in a network multiplies the integration surface area any AI deployment must account for, which means the organizations best positioned to deploy AI at scale are not necessarily those with the most capital, but those with the least fragmented data architecture.

Clinician trust and workflow fit remain a persistent, if increasingly well-understood, barrier. AI tools that do not surface within native EHR clinical workflows face systematic underutilization regardless of clinical validation quality — a pattern consistent across nearly every health system in this research sample, irrespective of size or region. Alert fatigue from earlier generations of rule-based clinical decision support has left a residual skepticism that newer, more sophisticated AI tools must actively work to overcome through workflow-native design rather than assuming clinical validity alone will drive adoption.

Governance and organizational readiness represent a less visible but equally significant barrier. Health systems that have scaled AI successfully share a common pattern of having built dedicated AI governance infrastructure — clinical AI oversight committees, model performance monitoring, clinician AI literacy programs — before rather than after enterprise deployment. Organizations that deployed AI tools ahead of this governance infrastructure report having to retrofit oversight processes under greater time pressure and with less organizational buy-in, a pattern Halkwinds' analysis identifies as one of the more expensive and avoidable implementation mistakes in this space.

• EHR fragmentation (avg. 3.2 systems per large network) is the #1 cited scaling barrier
• Clinician workflow fit outweighs clinical validation quality in driving actual utilization
• Governance infrastructure built before, not after, enterprise deployment correlates with successful scaling
• IT staffing and capital constraints disproportionately affect community and rural hospitals

Security and compliance risk in healthcare AI extends beyond standard HIPAA data protection to include AI-specific exposure: model training on inadequately de-identified patient data, third-party AI vendor access to protected health information without appropriate business associate agreements, and audit-trail gaps in generative AI outputs that make it difficult to reconstruct how a clinical recommendation was produced. Halkwinds' analysis is that HIPAA compliance in the context of AI model training and inference remains an area of active legal interpretation, and health systems should not assume that general HIPAA compliance programs adequately cover AI-specific data flows without dedicated review.

Regulatory reclassification risk is a distinct and underappreciated exposure. Tools initially positioned and deployed as lower-risk clinical decision support are, in a growing number of cases, being reclassified as regulated Software as a Medical Device as their autonomy level increases — and health systems that deployed these tools without ongoing regulatory monitoring face retroactive compliance questions and potential liability exposure. This risk is compounded in jurisdictions applying the EU AI Act's high-risk classification framework, where obligations attach based on system function and autonomy rather than a one-time approval at deployment.

Vendor concentration and lock-in risk is rising as the healthcare AI vendor market consolidates. Health systems building deep, proprietary integrations with a single AI-EHR vendor combination reduce near-term integration friction but increase switching costs and single-vendor dependency risk — a tradeoff that Halkwinds Research recommends health systems evaluate explicitly rather than defaulting to the path of least integration resistance. Algorithmic bias and health equity risk also warrant explicit governance attention: patient engagement AI tools, in particular, show strong utilization in digitally engaged populations but raise access and equity concerns for underserved patient populations that health system AI governance committees should monitor as a distinct risk category, not an implicit byproduct of broader deployment.

Clinical liability and malpractice exposure remains an evolving area of case law rather than settled practice. As AI-assisted diagnosis and clinical decision support tools take on higher-stakes recommendation roles, health systems and clinicians face genuine uncertainty about liability allocation between vendor, institution, and individual clinician when an AI-assisted recommendation contributes to an adverse outcome — an area Halkwinds recommends health system legal and risk teams treat as an active monitoring priority rather than a resolved question.

• AI-specific HIPAA exposure (model training data, vendor BAA coverage, audit-trail gaps)
• Regulatory reclassification risk as tools shift from decision-support to regulated SaMD status
• Vendor lock-in risk from deep, proprietary AI-EHR integrations
• Algorithmic bias and health equity risk in patient-facing AI tools
• Unsettled clinical liability allocation for AI-assisted diagnostic recommendations

Halkwinds Research projects the healthcare AI market will continue compounding at approximately its current 32.9% CAGR through 2030, reaching an estimated $187.4B, with the clinical AI segment closing much of its current gap with administrative AI as regulatory pathways mature and EHR-native AI reduces marginal deployment cost. The most consequential shift Halkwinds expects over this horizon is the extension of agentic AI — already emerging in prior authorization and denial management — into more autonomous administrative and, eventually, carefully scoped clinical workflows, following a maturation pattern similar to RAG's progression from pilot to 34% production deployment over the past two years.

Regulatory convergence, while unlikely to be complete, is a plausible medium-term trend. The FDA's SaMD guidance and the EU AI Act's high-risk classification framework are conceptually distinct but increasingly reference overlapping technical concepts — model monitoring, human oversight, and post-market surveillance — and Halkwinds' analysis is that health systems and vendors operating across both jurisdictions will benefit from designing to a common, more conservative compliance baseline rather than optimizing separately for each regime.

EHR fragmentation is likely to see gradual, not sudden, improvement over this horizon, driven less by M&A-related consolidation (which Halkwinds does not expect to reverse meaningfully) than by regulatory and market pressure toward FHIR-based interoperability standards. Health systems that invest in a FHIR integration façade now are, in Halkwinds' assessment, better positioned to absorb whatever the next wave of interoperability mandates requires than those that defer the investment pending EHR consolidation that may not materialize within this report's forecast horizon.

By 2028, Halkwinds expects clinical AI governance to have shifted from a differentiator among leading health systems to a baseline operating requirement across the industry, driven by a combination of regulatory pressure, malpractice risk management, and payer/accreditation expectations. Organizations that have not built this infrastructure by then will face a widening gap — not merely in AI capability, but in the institutional knowledge, vendor relationships, and governance maturity that newer entrants will need years to replicate.

Large health systems and IDNs (typically 500+ beds or multi-facility networks) should prioritize solving EHR fragmentation architecturally before expanding clinical AI deployment further, since every additional AI use case compounds the integration burden created by an unresolved multi-EHR environment. A FHIR-based integration façade, rather than point-to-point integration with each AI tool, is the more defensible long-term architecture and should be treated as foundational infrastructure investment rather than a cost center attached to any single AI initiative.

Enterprise organizations should establish a standing clinical AI governance committee — spanning clinical, regulatory, IT, and legal stakeholders — before, not after, scaling AI deployment enterprise-wide, following the pattern this research identifies among the most successful scalers. This committee should own regulatory monitoring for tools at risk of SaMD reclassification, model performance monitoring cadence, and clinician AI literacy programming as a coordinated function rather than distributing these responsibilities across disconnected teams.

Vendor strategy for enterprise health systems should explicitly weigh integration speed against lock-in risk rather than defaulting to the deepest available integration with an incumbent EHR vendor's native AI suite. Where build-vs-buy decisions arise — particularly for differentiated clinical workflows — enterprise organizations should evaluate custom development against off-the-shelf platforms using a structured framework rather than integration convenience alone; see Halkwinds' build vs. buy healthcare software comparison for a detailed decision framework.

• Solve EHR fragmentation architecturally (FHIR façade) before expanding clinical AI use cases
• Stand up a cross-functional clinical AI governance committee ahead of enterprise-wide scaling
• Evaluate vendor lock-in risk explicitly in AI-EHR integration decisions
• Use a structured build-vs-buy framework for differentiated clinical AI workflows

Mid-size hospitals and regional health networks (typically 200-499 beds) should prioritize administrative AI deployment ahead of clinical AI, given its clearer near-term ROI, lower regulatory bar, and lower organizational risk relative to clinical decision support — a sequencing that mirrors how the largest health systems in this research built AI governance capability before extending into higher-stakes clinical use cases. Revenue cycle management and prior authorization are the most defensible starting points given the payer-side AI pressure already reshaping this function.

Given more constrained IT staffing than large IDNs, mid-size systems should favor managed, EHR-native AI capability over custom-built integration wherever it meets clinical requirements, reserving custom development capacity for the small number of use cases where off-the-shelf tooling genuinely falls short. Partnering with vendors who bring pre-built HIPAA compliance and regulatory documentation, rather than building this capability internally, is typically the more capital-efficient path for organizations at this scale.

Mid-size systems should not defer governance investment on the assumption that their AI footprint is too small to warrant it. Even a single high-autonomy clinical AI tool carries the same regulatory reclassification and liability risk profile as it would at a larger institution; Halkwinds' recommendation is a lightweight but real governance structure — even a part-time AI oversight function reporting to the CMIO — rather than no formal governance at all.

• Sequence administrative AI before clinical AI to build organizational and governance muscle
• Favor managed, EHR-native AI capability over custom integration given IT staffing constraints
• Select vendors that bring pre-built compliance documentation rather than building internally
• Stand up lightweight governance even at smaller AI footprint — regulatory risk does not scale down proportionally

Startups building clinical or administrative AI products for health systems should treat regulatory strategy as a product design input from inception rather than a post-development compliance exercise — a lesson this research draws from the second wave of imaging AI vendors (2017-2021), where organizations with regulatory affairs expertise embedded early materially outperformed those that treated FDA clearance as a late-stage gate. Startups should also design for FHIR-native interoperability by default, since integration friction — not clinical validation — is the more common reason AI tools stall in health system procurement.

Whitespace analysis from this research suggests that RAG-based clinical documentation, while still growing, is approaching a more competitive and increasingly commoditized segment at 34% deployment; startups may find more durable differentiation in adjacent, less saturated categories such as agentic prior-authorization workflows, cross-EHR care coordination tooling that directly addresses the fragmentation problem this report identifies as the #1 scaling barrier, or clinical AI governance and monitoring tooling itself, which remains underserved relative to demand.

Startups should also build go-to-market strategy around the payer-provider AI asymmetry described in this report's Global Trends section — provider organizations facing competitive pressure from payer-side AI in revenue cycle functions represent a receptive, urgency-driven buying context that startups can address more credibly with clear ROI framing than with a purely clinical-outcomes pitch, particularly when selling into mid-size and community health systems with tighter capital constraints.

• Build regulatory strategy (FDA SaMD pathway awareness, EU AI Act classification) into product design from inception
• Default to FHIR-native architecture — integration friction stalls procurement more often than clinical validation gaps
• Consider less-saturated whitespace: agentic prior authorization, cross-EHR coordination, AI governance tooling
• Target the payer-provider AI asymmetry as a receptive, urgency-driven go-to-market wedge

The statistics and findings presented in this report that are not explicitly attributed below are Halkwinds Research estimates derived from the 312-health-system survey described in the Research Methodology section. The sources listed here are external, verified third-party research and regulatory publications cited for market context and regulatory framing; they are not Halkwinds data and should be consulted directly for their own methodology and findings.

• Gartner — research and market guides on AI in healthcare provider and payer technology strategy
• IDC — healthcare IT and AI spending forecasts and worldwide health industry insights publications
• McKinsey Global Institute and McKinsey & Company Healthcare Practice — research on generative AI value potential in healthcare delivery systems
• Deloitte Center for Health Solutions — health system CXO surveys and reports on AI governance and digital transformation in healthcare
• Forrester Research — healthcare technology and AI vendor landscape analyses
• U.S. Food and Drug Administration, Digital Health Center of Excellence — guidance on Software as a Medical Device (SaMD) and AI/ML-based medical device pathways
• U.S. Department of Health and Human Services, Office of the National Coordinator for Health IT (ONC) — interoperability and health IT policy publications
• European Commission — Regulation (EU) 2024/1689 (the EU Artificial Intelligence Act) and its classification framework for high-risk AI systems, including certain medical device applications
• U.K. Medicines and Healthcare products Regulatory Agency (MHRA) — guidance on software and AI as a medical device
• HL7 International — FHIR (Fast Healthcare Interoperability Resources) standard documentation

Halkwinds is a global AI-first software engineering company that designs, builds, and deploys enterprise technology at scale. Our portfolio spans AI/ML engineering, healthcare technology, SaaS platform development, cloud architecture, and enterprise systems integration, serving organizations from early-stage technology companies to Fortune 500 enterprises across healthcare, financial services, retail, and logistics. Our platforms — including AtlasIQ (enterprise intelligence), CareAxis (healthcare AI), and AstraFi (institutional DeFi) — represent our investment in productizing the AI capabilities we develop for clients. This research reflects our commitment to building a public knowledge commons around enterprise AI adoption: data and analysis that practitioners can rely on, cite, and use to make better technology investment decisions. For partnership inquiries, research access, or enterprise AI consulting, contact us at research@halkwinds.com.